Oncologists and pathologists are increasingly utilizing information on genomic alterations in tumors to help guide patient care and treatment. Personalis, Inc., a genomic sequencing and interpretation company, has developed a tumor-profiling test that provides clinicians with accurate and comprehensive analysis and clinical reporting of 181 genes to guide treatment decisions.

Learning Objectives
 

1. Understand the current industry challenges with regard to NGS technology and tumor profiling for clinical care.
2. Appreciate how the use of Personalis’ accuracy and content enhanced (ACE) sequencing platform with DNA & RNA analysis improves precision and reporting in solid tumor testing.
3. Recognize, through case studies, some of the more common molecular changes identified that may assist in therapeutic management.